TNFSF11 and postmenopausal osteoporosis: Due to the relevance of the RANK–RANKL signaling pathway, the RANKL-neutralizing antibody denosumab has been developed for the treatment of postmenopausal osteoporosis, bone metastases, and skeletal-related events (SRE) [15].